试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-09
PREA, PK And Safety PASS Study Of IV Pantoprazole In Pediatric Subjects
编号:NCT02401035登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:IV pantoprazole
登记的停止原因(原文):Study was terminated early due to the infeasibility of enrolling the required number of participants per protocol in the 1 \<2 years of age cohort.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-09
Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus
编号:NCT03428945登记状态:提前终止企业 / 申办者:National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
药物 / 成分:Hydroxychloroquine、Placebo
登记的停止原因(原文):This trial has undergone a prespecified interim analysis which determined that this treatment provides no statistically significant delay in the onset of abnormal glucose tolerance or Type 1 Diabetes.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-09
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
编号:NCT03472560登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:Avelumab (MSB0010718C)、Axitinib (AG-013736)
登记的停止原因(原文):The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the Investigational treatments have been moved to a continuation study (NCT05059522)
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-09
A Study of Olaparib and Durvalumab in Prostate Cancer
编号:NCT03810105登记状态:提前终止企业 / 申办者:Memorial Sloan Kettering Cancer Center
药物 / 成分:Olaparib、Durvalumab
登记的停止原因(原文):Due to low accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-09
Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC
编号:NCT04659369登记状态:提前终止企业 / 申办者:Taizhou Mabtech Pharmaceutical Co.,Ltd
药物 / 成分:CMAB819、Nivolumab
登记的停止原因(原文):Difficult to recruit subjects
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-09
Ursodeoxycholic Acid in C. Difficile Infection
编号:NCT05526807登记状态:提前终止企业 / 申办者:Nottingham University Hospitals NHS Trust
药物 / 成分:Ursodeoxycholic acid
登记的停止原因(原文):Slow recruitment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-08
A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures
编号:NCT03325439登记状态:提前终止企业 / 申办者:UCB Biopharma SRL
药物 / 成分:Brivaracetam (BRV) intravenous (iv)、Brivaracetam (BRV) oral
登记的停止原因(原文):Terminated (The study stopped prematurely due to enrolment challenges, the termination was not linked to any safety issues.)
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-08
Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma
编号:NCT03927222登记状态:提前终止企业 / 申办者:Mustafa Khasraw, MBChB, MD, FRCP, FRACP
药物 / 成分:Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF、Temozolomide、Tetanus-Diphtheria Toxoid (Td)、GM-CSF
登记的停止原因(原文):Resource shortage
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-05
Postpartum Low-Dose Aspirin After Preeclampsia for Optimization of Cardiovascular Risk (PAPVASC)
编号:NCT04243278登记状态:提前终止企业 / 申办者:Dr. Graeme Smith
药物 / 成分:Low-dose aspirin、Placebo oral tablet
登记的停止原因(原文):Poor Recruitment Rates
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-05
Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)
编号:NCT04809623登记状态:提前终止企业 / 申办者:Gilead Sciences
药物 / 成分:Edecesertib、Placebo、Standard of Care
登记的停止原因(原文):Sponsor decision to terminate study.
查看官方原始记录 ↗